Evidence map›Paper›PMID 40007992›Full record

ArticleFrontiers in oncology2025

Diagnosis and treatment of thyroblastoma: a case report and review of literature.

Xiting Chen, Lijuan Xiong, Hongling Liu, Haoqiang Wang, Donghai Cheng, Wei Wang, Wenyuan He, Bo Xie, Juan Zhou

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiting Chen *Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Lijuan Xiong *Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Hongling LiuDepartment of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Haoqiang WangDepartment of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Donghai ChengDepartment of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Wei WangDepartment of Pathology, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Wenyuan HeDepartment of Pathology, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Bo XieDepartment of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Juan ZhouDepartment of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: The diagnosis of thyroblastoma initially identified as a thyroid malignant teratoma was subsequently classified as a distinct entity by the World Health Organization (WHO) in 2022. This classification was based on the observation that the tumor presents with independent primitive multilineage elements and is frequently associated with DICER1 hotspot mutations.The objective of this study was to explore and investigate the clinicopathologic characteristics, molecular features and treatment strategies of patients with thyroblastoma, followed by a review of the previous relevant literature. Methods: The clinical manifestations, pathological characteristics, molecular features and treatment strategies of the initial case of thyroblastoma pathologically confirmed in China were analyzed. Results: The tumor was revealed to have high invasive potential, rapid disease progression, and primitive multilineage elements of pathology, including immature thyroid epithelium, spindled mesenchymal proliferations, and neuroepithelial blastema. Next-generation sequencing (NGS) confirmed the presence of germline DICER1 heterozygous pathogenic mutation at p.G1784* in patient, accompanied by the somatic hotspot mutation at p.E1813D of the RNase IIIb domain. Despite local thyroid tumor resection, the disease continued to progress rapidly. However, chemotherapy with BEP led to a reduction in the tumor. The patient's progression-free survival (PFS) reached 15 months following the administration of BEP chemotherapy in conjunction with local radiotherapy. The patient ultimately died of cardiac arrest resulting from the progression of the cancer thrombus to the right atrium and right ventricle. Conclusion: Although thyroblastoma has been treated as a separate entity with its distinctive morphologic and molecular characteristics, its clinicopathological features, diagnosis and treatment methods and prognosis remain poorly understood, which requires more accumulated clinical case data to provide basis for the correct diagnosis and treatment in the future.

Indexed as

diagnosis and treatmentDICER1thyroblastomathyroidthyroid neoplasms

Identifiers

PMID40007992
PMCPMC11850407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.